25 XP   0   0   10

Immuron Ltd
Buy, Hold or Sell?

Let's analyse Immuron together

PenkeI guess you are interested in Immuron Ltd. Buy, hold or sell? I don't know! However, I do recommend doing research before doing anything. I will help you with that.

I'm going to help you getting a better view of Immuron Ltd. At the end you don't have to ask anyone for trading advice. You can make your own decision, with more confidence, the odds in your favor, backed by data.

You can find me behind Let's Analyse Together in the top-right of each section.

Get notifications about Immuron Ltd

I send you an email if I find something interesting about Immuron Ltd.

Quick analysis of Immuron (30 sec.)










What can you expect buying and holding a share of Immuron? (30 sec.)

How much money do you get?

How much money do you get?
A$0.00
When do you have the money?
1 year
How often do you get paid?
0.0%

What is your share worth?

Current worth
A$0.09
Expected worth in 1 year
A$0.02
How sure are you?
50.0%

+ What do you gain per year?

Total Gains per Share
A$-0.06
Return On Investment
-62.5%

For what price can you sell your share?

Current Price per Share
A$0.10
Expected price per share
A$0.091 - A$0.135
How sure are you?
50%

1. Valuation of Immuron (5 min.)




Live pricePrice per Share (EOD)

A$0.10

Intrinsic Value Per Share

A$-0.12 - A$-0.07

Total Value Per Share

A$-0.04 - A$0.02

2. Growth of Immuron (5 min.)




Is Immuron growing?

Current yearPrevious yearGrowGrow %
How rich?$12.5m$14.8m-$2.2m-18.2%

How much money is Immuron making?

Current yearPrevious yearGrowGrow %
Making money-$2.4m-$1.8m-$598.6k-24.6%
Net Profit Margin-209.8%-373.0%--

How much money comes from the company's main activities?

3. Financial Health of Immuron (5 min.)




4. Comparing to competitors in the Biotechnology industry (5 min.)




  Industry Rankings (Biotechnology)  


Richest
#653 / 1014

Most Revenue
#488 / 1014

Most Profit
#327 / 1014

Most Efficient
#642 / 1014

What can you expect buying and holding a share of Immuron? (5 min.)

Welcome investor! Immuron's management wants to use your money to grow the business. In return you get a share of Immuron.

What can you expect buying and holding a share of Immuron?

First you should know what it really means to hold a share of Immuron. And how you can make/lose money.

Speculation

The Price per Share of Immuron is A$0.1. The market price reflects what other people think it is worth; not what it's really worth. Your job is to find out if the market price is fair, overpriced, or underpriced. I will help you with that.

If you buy blind, there is a 50% chance of making or losing money by selling the stock in the future. However, we can look at a few things to determine the odds in our favor:

  • The fundamentals: the financial health trends of Immuron.
  • The technials: based on market psychology, we can make a calculated estimate of what the price will do in the future. We can do this through technical analysis. We can calculate the probabilities and the expected value (millionaire math). That's called speculation.
  • The book value: what is the market price compared to it's book value.

Investing

If you really want to invest in Immuron, you will have to let go of the thought of selling in the future. If you have to sell the share for less than you bought it, it can still be a good investment. Focus on what it means to hold the stock forever:

  • You own a part of the company. The equity of this part can grow or shrink. The current Book Value per Share is A$0.09. Based on the TTM, the Book Value Change Per Share is A$-0.02 per quarter. Based on the YOY, the Book Value Change Per Share is A$-0.01 per quarter.
  • You may receive quarterly/yearly dividend in the form of additional shares.
  • You may receive quarterly/yearly dividend in the form of cash. Based on the TTM the Dividend per Share is A$0.00 per quarter.
Based on historical numbers we can estimate the returns while holding a share of Immuron.

How much money are you going to get?

 MRQTTMYOY5Y10Y
 A$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per ShareA$% of Price per Share
Usd Eps-0.01-10.7%-0.01-10.7%-0.01-8.0%-0.01-12.7%-0.01-12.4%
Usd Book Value Change Per Share-0.01-10.0%-0.01-10.0%-0.01-7.7%0.016.3%0.015.5%
Usd Dividend Per Share0.000.0%0.000.0%0.000.0%0.000.0%0.000.0%
Usd Total Gains Per Share-0.01-10.0%-0.01-10.0%-0.01-7.7%0.016.3%0.015.5%
Usd Price Per Share0.05-0.05-0.05-0.09-0.11-
Price to Earnings Ratio-4.51--4.51--6.30--8.25--10.19-
Price-to-Total Gains Ratio-4.80--4.80--6.62--13.89-3.03-
Price to Book Ratio0.87-0.87-0.78-3.45-6.32-
Price-to-Total Gains Ratio-4.80--4.80--6.62--13.89-3.03-

When do you get the money?

Usd Investment
$.00
Usd Price Per Share0.06421
Number of shares15573
Gains per QuarterTrailing 12 Months5 Year
Usd Dividend Per Share0.000.00
Usd Book Value Change Per Share-0.010.01
Usd Total Gains Per Share-0.010.01
Gains per Quarter (15573 shares)-156.3098.13
Gains per Year (15573 shares)-625.18392.52
YearsReturn on Investment (TTM)Return on Investment (5Y)
 DividendBook Value gainTotal gainsDividendBook Value gainTotal gains
Broker costs---10---10
10-625-6350393383
20-1250-12600785776
30-1876-1885011781169
40-2501-2510015701562
50-3126-3135019631955
60-3751-3760023552348
70-4376-4385027482741
80-5001-5010031403134
90-5627-5635035333527
100-6252-6260039253920

How sure are you?

Based on the past periods, how sure are you to get value out of your investment.

Linear %
 Trailing 12 Months3Y5 Year10 YearALLTIME
  % % % % %
Earnings Per Share0.01.00.00.0%0.03.00.00.0%0.05.00.00.0%0.010.00.00.0%0.022.02.00.0%
Book Value Change Per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%5.05.00.050.0%10.014.00.041.7%
Dividend per Share0.00.01.00.0%0.00.03.00.0%0.00.05.00.0%0.00.010.00.0%0.00.024.00.0%
Total Gains per Share0.01.00.00.0%1.02.00.033.3%1.04.00.020.0%5.05.00.050.0%10.014.00.041.7%

Fundamentals of Immuron

About Immuron Ltd

Immuron Limited, a biopharmaceutical company, engages in the research, development, and commercialization of polyclonal antibodies in Australia, Israel, Canada, the United States, and internationally. The company operates through two segments, Research and Development, and Hyperimmune Products. It offers Travelan, an over-the-counter medicine to reduce the risk of travelers' diarrhea and risk of minor gastrointestinal disorders, as well as a dietary supplement for support digestive health and gastrointestinal tract protection; and Protectyn, an immune supplement to help maintain a healthy digestive function and liver. The company is also developing Travelan (IMM-124E) to reduce the risk of contracting travelers' diarrhea in the United States, and Travelers' Diarrhea; and IMM-529, for treating patients suffering from recurring clostridium difficile infection. It has a research agreement with Naval Medical Research Center to develop and clinically evaluate a therapeutic targeting Campylobacter and enterotoxigenic Escherichia coli infections; and a collaboration agreement with the Walter Reed Army Institute of Research to develop an oral therapeutic for shigellosis. Immuron Limited was incorporated in 1994 and is headquartered in Carlton, Australia.

Fundamental data was last updated by Penke on 2024-04-22 09:55:05.

Financial Health

Profitability Details
 Compared to previous yearCompared to industry
The company is making a huge loss.
Using its assets, the company is very inefficient in making profit.
Using its investors money, the company is very inefficient in making profit.
Operating Efficiency Details
 Compared to previous yearCompared to industry
The company is operating very inefficient.
The company is inefficient in keeping operating costs low.
Liquidity Details
 Compared to previous yearCompared to industry
The company is very able to pay all its short-term debts.
The company is very able to pay all its short-term debts with the most liquid assets.
Solvency Details
 Compared to previous yearCompared to industry
The company is very able to pay all its debts by selling its assets.
The company is very able to pay all its debts with equity.

Valuation

Valuation Details
 Compared to previous yearCompared to industry
Based on the equity, the company is cheap.
Based on the earnings, the company is expensive.
Based on how much money comes from the company's main activities, the company is expensive.

1.1. Profitability of Immuron Ltd.

1.1. Profitability
1.1.1. Net Profit Margin

Measures how much net profit Immuron earns for each $1 of revenue.

  • Above 10% is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • A Net Profit Margin of -209.8% means that $-2.10 for each $1 in revenue is generated as profit.

Let's take a look of the Net Profit Margin trends of Immuron Ltd:

  • The MRQ is -209.8%. The company is making a huge loss. -2
  • The TTM is -209.8%. The company is making a huge loss. -2
Trends
Current periodCompared to+/- 
MRQ-209.8%TTM-209.8%0.0%
TTM-209.8%YOY-373.0%+163.2%
TTM-209.8%5Y-1,329.0%+1,119.2%
5Y-1,329.0%10Y-851.4%-477.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-209.8%-196.1%-13.7%
TTM-209.8%-211.9%+2.1%
YOY-373.0%-277.7%-95.3%
5Y-1,329.0%-432.9%-896.1%
10Y-851.4%-599.3%-252.1%
1.1.2. Return on Assets

Shows how efficient Immuron is using its assets to generate profit.

  • Above 5% is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • -17.2% Return on Assets means that Immuron generated $-0.17 profit for each $1 in assets.

Let's take a look of the Return on Assets trends of Immuron Ltd:

  • The MRQ is -17.2%. Using its assets, the company is very inefficient in making profit. -2
  • The TTM is -17.2%. Using its assets, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-17.2%TTM-17.2%0.0%
TTM-17.2%YOY-11.5%-5.7%
TTM-17.2%5Y-32.2%+15.0%
5Y-32.2%10Y-44.8%+12.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-17.2%-13.3%-3.9%
TTM-17.2%-12.7%-4.5%
YOY-11.5%-11.8%+0.3%
5Y-32.2%-14.0%-18.2%
10Y-44.8%-15.9%-28.9%
1.1.3. Return on Equity

Shows how efficient Immuron is using its investors money to generate profit.

  • Above 15%-20% is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • -19.3% Return on Equity means Immuron generated $-0.19 for each $1 the owners (shareholders) invested.

Let's take a look of the Return on Equity trends of Immuron Ltd:

  • The MRQ is -19.3%. Using its investors money, the company is very inefficient in making profit. -2
  • The TTM is -19.3%. Using its investors money, the company is very inefficient in making profit. -2
Trends
Current periodCompared to+/- 
MRQ-19.3%TTM-19.3%0.0%
TTM-19.3%YOY-12.3%-7.0%
TTM-19.3%5Y-35.8%+16.5%
5Y-35.8%10Y-57.9%+22.1%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-19.3%-16.9%-2.4%
TTM-19.3%-16.0%-3.3%
YOY-12.3%-15.1%+2.8%
5Y-35.8%-19.7%-16.1%
10Y-57.9%-20.5%-37.4%

1.2. Operating Efficiency of Immuron Ltd.

1.2. Operating Efficiency
1.2.1. Operating Margin

Measures how efficient Immuron is operating .

  • Measures how much profit Immuron makes for each $1 of sales after paying variable costs (production costs, wages, etc) but before taxes.
  • Above 15% is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • An Operating Margin of -332.5% means the company generated $-3.32  for each $1 in revenue (before taxes).

Let's take a look of the Operating Margin trends of Immuron Ltd:

  • The MRQ is -332.5%. The company is operating very inefficient. -2
  • The TTM is -332.5%. The company is operating very inefficient. -2
Trends
Current periodCompared to+/- 
MRQ-332.5%TTM-332.5%0.0%
TTM-332.5%YOY-530.5%+198.0%
TTM-332.5%5Y-1,392.7%+1,060.2%
5Y-1,392.7%10Y-868.0%-524.6%
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ-332.5%-290.9%-41.6%
TTM-332.5%-224.4%-108.1%
YOY-530.5%-288.3%-242.2%
5Y-1,392.7%-479.5%-913.2%
10Y-868.0%-625.2%-242.8%
1.2.2. Operating Ratio

Measures how efficient Immuron is keeping operating costs low.

  • Below 1 is considered healthy (always compare to Biotechnology industry mean).
  • An Operation Ratio of 4.32 means that the operating costs are $4.32 for each $1 in net sales.

Let's take a look of the Operating Ratio trends of Immuron Ltd:

  • The MRQ is 4.325. The company is inefficient in keeping operating costs low. -1
  • The TTM is 4.325. The company is inefficient in keeping operating costs low. -1
Trends
Current periodCompared to+/- 
MRQ4.325TTM4.3250.000
TTM4.325YOY6.305-1.980
TTM4.3255Y14.927-10.602
5Y14.92710Y9.771+5.156
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ4.3253.110+1.215
TTM4.3253.266+1.059
YOY6.3053.783+2.522
5Y14.9275.657+9.270
10Y9.7717.783+1.988

1.3. Liquidity of Immuron Ltd.

1.3. Liquidity
1.3.1. Current Ratio

Measures if Immuron is able to pay off Short-term Debt.

  • Above 1.5 is considered healthy (always compare to Biotechnology industry mean).
  • A Current Ratio of 9.20 means the company has $9.20 in assets for each $1 in short-term debts.

Let's take a look of the Current Ratio trends of Immuron Ltd:

  • The MRQ is 9.197. The company is very able to pay all its short-term debts. +2
  • The TTM is 9.197. The company is very able to pay all its short-term debts. +2
Trends
Current periodCompared to+/- 
MRQ9.197TTM9.1970.000
TTM9.197YOY15.750-6.553
TTM9.1975Y12.406-3.209
5Y12.40610Y9.066+3.340
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.1973.905+5.292
TTM9.1974.212+4.985
YOY15.7505.337+10.413
5Y12.4066.062+6.344
10Y9.0666.401+2.665
1.3.2. Quick Ratio

Measures if Immuron is able to pay off Short-term Debt but only using the most liquid assets.

  • Above 1 is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • A Quick Ratio of 9.57 means the company can pay off $9.57 for each $1 in debt (using most liquid assets).

Let's take a look of the Quick Ratio trends of Immuron Ltd:

  • The MRQ is 9.574. The company is very able to pay all its short-term debts with the most liquid assets. +2
  • The TTM is 9.574. The company is very able to pay all its short-term debts with the most liquid assets. +2
Trends
Current periodCompared to+/- 
MRQ9.574TTM9.5740.000
TTM9.574YOY16.372-6.799
TTM9.5745Y12.119-2.545
5Y12.11910Y8.430+3.689
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ9.5743.572+6.002
TTM9.5744.001+5.573
YOY16.3725.364+11.008
5Y12.1196.009+6.110
10Y8.4306.287+2.143

1.4. Solvency of Immuron Ltd.

1.3. Liquidity
1.4.1. Debt to Asset Ratio

Measures how much % of Immuron assets are financed with debt.

  • Below 1 (100%) is considered healthy but always compare Immuron to Biotechnology industry mean.
  • A Debt to Asset Ratio of 0.11 means that Immuron assets are financed with 10.8% credit (debt) and the remaining percentage (100% - 10.8%) is financed by its owners/shareholders. 

Let's take a look of the Debt to Asset Ratio trends of Immuron Ltd:

  • The MRQ is 0.108. The company is very able to pay all its debts by selling its assets. +2
  • The TTM is 0.108. The company is very able to pay all its debts by selling its assets. +2
Trends
Current periodCompared to+/- 
MRQ0.108TTM0.1080.000
TTM0.108YOY0.068+0.040
TTM0.1085Y0.090+0.018
5Y0.09010Y0.156-0.066
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1080.336-0.228
TTM0.1080.334-0.226
YOY0.0680.271-0.203
5Y0.0900.366-0.276
10Y0.1560.389-0.233
1.4.2. Debt to Equity Ratio

Measures if Immuron is able to pay off its debts by using shareholders equity.

  • Below 2 is considered healthy but always compare Immuron to the Biotechnology industry mean.
  • A Debt to Equity ratio of 12.1% means that company has $0.12 debt for each $1 in shareholders equity.

Let's take a look of the Debt to Equity Ratio trends of Immuron Ltd:

  • The MRQ is 0.121. The company is very able to pay all its debts with equity. +2
  • The TTM is 0.121. The company is very able to pay all its debts with equity. +2
Trends
Current periodCompared to+/- 
MRQ0.121TTM0.1210.000
TTM0.121YOY0.072+0.048
TTM0.1215Y0.100+0.021
5Y0.10010Y0.213-0.113
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
MRQ0.1210.382-0.261
TTM0.1210.397-0.276
YOY0.0720.341-0.269
5Y0.1000.432-0.332
10Y0.2130.465-0.252

2. Market Valuation of Immuron Ltd

2.1. Earnings Per Share
2.1. Price to Earnings Ratio

Measures how much money you pay for each share for every $1 in earnings Immuron generates.

  • Above 15 is considered overpriced but always compare Immuron to the Biotechnology industry mean.
  • A PE ratio of -4.51 means the investor is paying $-4.51 for every $1 in earnings.

Let's take a look of the Price to Earnings Ratio trends of Immuron Ltd:

  • The EOD is -6.016. Based on the earnings, the company is expensive. -2
  • The MRQ is -4.512. Based on the earnings, the company is expensive. -2
  • The TTM is -4.512. Based on the earnings, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-6.016MRQ-4.512-1.504
MRQ-4.512TTM-4.5120.000
TTM-4.512YOY-6.305+1.793
TTM-4.5125Y-8.254+3.742
5Y-8.25410Y-10.185+1.932
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-6.016-2.262-3.754
MRQ-4.512-2.599-1.913
TTM-4.512-2.674-1.838
YOY-6.305-4.133-2.172
5Y-8.254-6.258-1.996
10Y-10.185-6.171-4.014
2.2. Price To Free Cash Flow Ratio

Let's take a look of the Price To Free Cash Flow Ratio trends of Immuron Ltd:

  • The EOD is -9.126. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The MRQ is -6.844. Based on how much money comes from the company's main activities, the company is expensive. -2
  • The TTM is -6.844. Based on how much money comes from the company's main activities, the company is expensive. -2
Trends
Current periodCompared to+/- 
EOD-9.126MRQ-6.844-2.281
MRQ-6.844TTM-6.8440.000
TTM-6.844YOY-5.727-1.117
TTM-6.8445Y-11.075+4.231
5Y-11.07510Y-11.482+0.407
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD-9.126-2.913-6.213
MRQ-6.844-3.275-3.569
TTM-6.844-3.508-3.336
YOY-5.727-5.620-0.107
5Y-11.075-8.306-2.769
10Y-11.482-8.854-2.628
2. Book Value per Share
2.3. Price to Book Ratio

Measures if the stock price of Immuron is to cheap or to expensive compared to its book value.

  • At or below 1 is considered healthy (always compare to Biotechnology industry mean).
  • A PB ratio of 0.87 means the investor is paying $0.87 for each $1 in book value.

Let's take a look of the Price to Book Ratio trends of Immuron Ltd:

  • The EOD is 1.161. Based on the equity, the company is underpriced. +1
  • The MRQ is 0.871. Based on the equity, the company is cheap. +2
  • The TTM is 0.871. Based on the equity, the company is cheap. +2
Trends
Current periodCompared to+/- 
EOD1.161MRQ0.871+0.290
MRQ0.871TTM0.8710.000
TTM0.871YOY0.776+0.094
TTM0.8715Y3.454-2.583
5Y3.45410Y6.318-2.864
Compared to industry (Biotechnology)
PeriodCompanyIndustry (mean)+/- 
EOD1.1611.858-0.697
MRQ0.8712.090-1.219
TTM0.8712.091-1.220
YOY0.7762.866-2.090
5Y3.4543.488-0.034
10Y6.3183.836+2.482
2. Total Gains per Share

3. Holders & Insider Transactions

Let's take a look at which institutions, funds and insiders are holding shares of Immuron Ltd.

4. Summary

4.1. Key Performance Indicators

The key performance indicators of Immuron Ltd compared to the Most Recent Quarter (MRQ).

 End of day+/-Most Recent QuarterTrailing 12 Months+/-Year-Over-Year+/-5 Year+/-10 Year+/-
Book Value Change Per Share---0.016-0.0160%-0.012-24%0.010-259%0.009-283%
Book Value Per Share--0.0860.0860%0.102-15%0.072+20%0.049+76%
Current Ratio--9.1979.1970%15.750-42%12.406-26%9.066+1%
Debt To Asset Ratio--0.1080.1080%0.068+60%0.090+20%0.156-31%
Debt To Equity Ratio--0.1210.1210%0.072+67%0.100+20%0.213-43%
Dividend Per Share----0%-0%-0%-0%
Eps---0.017-0.0170%-0.013-25%-0.020+19%-0.019+16%
Free Cash Flow Per Share---0.011-0.0110%-0.014+26%-0.013+18%-0.016+45%
Free Cash Flow To Equity Per Share---0.011-0.0110%-0.014+26%0.013-185%0.008-238%
Gross Profit Margin--1.2451.2450%1.146+9%1.182+5%1.133+10%
Intrinsic Value_10Y_max---0.066--------
Intrinsic Value_10Y_min---0.124--------
Intrinsic Value_1Y_max---0.012--------
Intrinsic Value_1Y_min---0.015--------
Intrinsic Value_3Y_max---0.031--------
Intrinsic Value_3Y_min---0.043--------
Intrinsic Value_5Y_max---0.046--------
Intrinsic Value_5Y_min---0.069--------
Market Cap22779800.000+25%17084875.95017084875.9500%17996042.000-5%31618367.590-46%40753064.795-58%
Net Profit Margin---2.098-2.0980%-3.730+78%-13.290+533%-8.514+306%
Operating Margin---3.325-3.3250%-5.305+60%-13.927+319%-8.680+161%
Operating Ratio--4.3254.3250%6.305-31%14.927-71%9.771-56%
Pb Ratio1.161+25%0.8710.8710%0.776+12%3.454-75%6.318-86%
Pe Ratio-6.016-33%-4.512-4.5120%-6.305+40%-8.254+83%-10.185+126%
Price Per Share0.100+25%0.0750.0750%0.079-5%0.139-46%0.179-58%
Price To Free Cash Flow Ratio-9.126-33%-6.844-6.8440%-5.727-16%-11.075+62%-11.482+68%
Price To Total Gains Ratio-6.398-33%-4.798-4.7980%-6.622+38%-13.887+189%3.031-258%
Quick Ratio--9.5749.5740%16.372-42%12.119-21%8.430+14%
Return On Assets---0.172-0.1720%-0.115-33%-0.322+87%-0.448+160%
Return On Equity---0.193-0.1930%-0.123-36%-0.358+86%-0.579+200%
Total Gains Per Share---0.016-0.0160%-0.012-24%0.010-259%0.009-283%
Usd Book Value--12595970.39612595970.3960%14882209.182-15%10489903.328+20%7176556.887+76%
Usd Book Value Change Per Share---0.010-0.0100%-0.008-24%0.006-259%0.005-283%
Usd Book Value Per Share--0.0550.0550%0.065-15%0.046+20%0.032+76%
Usd Dividend Per Share----0%-0%-0%-0%
Usd Eps---0.011-0.0110%-0.008-25%-0.013+19%-0.012+16%
Usd Free Cash Flow---1602850.472-1602850.4720%-2017632.304+26%-1887092.603+18%-2319064.351+45%
Usd Free Cash Flow Per Share---0.007-0.0070%-0.009+26%-0.008+18%-0.010+45%
Usd Free Cash Flow To Equity Per Share---0.007-0.0070%-0.009+26%0.008-185%0.005-238%
Usd Market Cap14626909.580+25%10970198.84710970198.8470%11555258.568-5%20302153.830-46%26167542.905-58%
Usd Price Per Share0.064+25%0.0480.0480%0.051-5%0.089-46%0.115-58%
Usd Profit---2431316.145-2431316.1450%-1832716.493-25%-2901931.268+19%-2871304.960+18%
Usd Revenue--1158801.0811158801.0810%491330.425+136%978774.348+18%893056.502+30%
Usd Total Gains Per Share---0.010-0.0100%-0.008-24%0.006-259%0.005-283%
 EOD+5 -3MRQTTM+0 -0YOY+13 -215Y+19 -1510Y+22 -12

4.2. Fundamental Score

Let's check the fundamental score of Immuron Ltd based on Penke's default stock scanner.

Penke's Stock Scanner

  
  
IndicatorConditionValue
Price to Earnings Ratio (EOD)Between0-15-6.016
Price to Book Ratio (EOD)Between0-11.161
Net Profit Margin (MRQ)Greater than0-2.098
Operating Margin (MRQ)Greater than0-3.325
Quick Ratio (MRQ)Greater than19.574
Current Ratio (MRQ)Greater than19.197
Debt to Asset Ratio (MRQ)Less than10.108
Debt to Equity Ratio (MRQ)Less than10.121
Return on Equity (MRQ)Greater than0.15-0.193
Return on Assets (MRQ)Greater than0.05-0.172
Total4/10 (40.0%)

4.3. Technical Score

Let's check the technical score of Immuron Ltd based on Penke's default Symbol scanner.

Penke's Symbol Scanner

  
  
IndicatorConditionValue
OpenGreater thanClose0.099
Total0/1 (0.0%)



Latest Balance Sheet

Balance Sheet of 2023-06-30. Currency in AUD. All numbers in thousands.

Summary
Total Assets21,988
Total Liabilities2,371
Total Stockholder Equity19,617
 As reported
Total Liabilities 2,371
Total Stockholder Equity+ 19,617
Total Assets = 21,988

Assets

Total Assets21,988
Total Current Assets20,409
Long-term Assets1,579
Total Current Assets
Cash And Cash Equivalents 17,160
Short-term Investments 1,834
Net Receivables 417
Inventory 840
Other Current Assets 158
Total Current Assets  (as reported)20,409
Total Current Assets  (calculated)20,409
+/-0
Long-term Assets
Property Plant Equipment 200
Long Term Investments 159
Long-term Assets Other 1,220
Long-term Assets  (as reported)1,579
Long-term Assets  (calculated)1,579
+/-0

Liabilities & Shareholders' Equity

Total Current Liabilities2,219
Long-term Liabilities152
Total Stockholder Equity19,617
Total Current Liabilities
Short-term Debt 39
Accounts payable 791
Other Current Liabilities 691
Total Current Liabilities  (as reported)2,219
Total Current Liabilities  (calculated)1,521
+/- 698
Long-term Liabilities
Capital Lease Obligations Min Short Term Debt150
Other Liabilities 2
Long-term Liabilities  (as reported)152
Long-term Liabilities  (calculated)152
+/- 0
Total Stockholder Equity
Common Stock88,436
Retained Earnings -72,055
Accumulated Other Comprehensive Income 3,236
Total Stockholder Equity (as reported)19,617
Total Stockholder Equity (calculated)19,617
+/-0
Other
Capital Stock88,436
Cash and Short Term Investments 18,994
Common Stock Shares Outstanding 227,798
Current Deferred Revenue698
Liabilities and Stockholders Equity 21,988
Net Debt -16,971
Net Invested Capital 19,617
Net Tangible Assets 19,617
Net Working Capital 18,190
Property Plant and Equipment Gross 651
Short Long Term Debt Total 189



Balance Sheet

Currency in AUD. All numbers in thousands.

 Trend2023-06-302022-06-302021-06-302020-06-302019-06-302018-06-302017-06-302016-06-302015-06-302014-06-302013-06-302012-06-302011-06-302010-06-302009-06-302008-06-302007-06-302006-06-302005-06-302004-06-302003-06-302002-06-302001-06-302000-06-301999-06-30
> Total Assets 
0
4,503
7,831
6,577
5,955
4,910
8,055
6,625
3,296
1,900
493
3,798
2,660
3,638
2,527
7,632
4,549
8,827
8,286
9,243
8,562
6,202
27,053
24,856
21,988
21,98824,85627,0536,2028,5629,2438,2868,8274,5497,6322,5273,6382,6603,7984931,9003,2966,6258,0554,9105,9556,5777,8314,5030
   > Total Current Assets 
0
0
5,563
4,365
0
2,848
6,041
4,998
2,654
1,677
422
2,306
1,171
2,219
1,838
7,612
4,529
8,809
8,268
7,050
6,682
4,409
25,753
23,672
20,409
20,40923,67225,7534,4096,6827,0508,2688,8094,5297,6121,8382,2191,1712,3064221,6772,6544,9986,0412,84804,3655,56300
       Cash And Cash Equivalents 
0
356
307
576
382
312
179
1,434
673
1,091
150
1,882
751
1,444
1,447
6,142
3,116
2,291
3,995
4,727
5,120
3,250
25,047
22,110
17,160
17,16022,11025,0473,2505,1204,7273,9952,2913,1166,1421,4471,4447511,8821501,0916731,4341793123825763073560
       Short-term Investments 
0
4,000
4,536
2,800
2,130
1,000
3,479
1,100
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,834
1,834
1,8341,8340000000000000001,1003,4791,0002,1302,8004,5364,0000
       Net Receivables 
0
29
389
520
654
605
968
816
1,011
269
28
153
34
205
15
518
222
4,388
1,768
1,683
969
328
335
663
417
4176633353289691,6831,7684,3882225181520534153282691,011816968605654520389290
       Other Current Assets 
0
21
15
40
47
128
126
59
145
155
148
249
96
356
84
387
45
481
305
142
49
33
78
572
158
15857278334914230548145387843569624914815514559126128474015210
   > Long-term Assets 
0
0
2,269
2,212
0
2,062
2,014
0
0
0
0
1,492
1,489
1,419
689
0
0
18
19
2,192
1,879
1,793
1,300
1,184
1,579
1,5791,1841,3001,7931,8792,1921918006891,4191,4891,49200002,0142,06202,2122,26900
       Property Plant Equipment 
0
7
1,922
1,883
1,830
1,769
1,739
1,627
642
223
71
31
28
18
8
20
20
18
19
20
17
71
34
227
200
20022734711720191820208182831712236421,6271,7391,7691,8301,8831,92270
       Goodwill 
0
0
347
329
311
293
275
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
00000000000000000027529331132934700
       Long Term Investments 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
159
159000000000000000000000000
       Intangible Assets 
0
0
347
329
311
293
275
0
0
0
0
1,461
1,461
1,401
681
0
0
0
0
0
0
0
0
0
0
00000000006811,4011,4611,461000027529331132934700
       Other Assets 
0
0
0
0
0
2,062
2,014
1,627
642
223
71
1,492
1,489
1,419
689
20
20
800
0
2,172
1,862
0
1,267
0
0
001,26701,8622,172080020206891,4191,4891,492712236421,6272,0142,06200000
> Total Liabilities 
0
61
356
254
911
878
1,114
1,447
1,376
813
678
435
928
1,588
2,382
845
1,208
3,887
1,712
803
1,211
558
1,158
1,678
2,371
2,3711,6781,1585581,2118031,7123,8871,2088452,3821,5889284356788131,3761,4471,114878911254356610
   > Total Current Liabilities 
0
61
356
254
870
832
1,092
1,386
1,312
790
676
433
928
1,029
1,235
845
1,208
3,887
1,712
803
1,196
516
1,122
1,503
2,219
2,2191,5031,1225161,1968031,7123,8871,2088451,2351,0299284336767901,3121,3861,092832870254356610
       Short-term Debt 
0
0
4,536
2,800
0
27
3,479
1,100
0
0
0
0
0
0
0
0
0
1,901
366
0
42
42
20
34
39
393420424203661,9010000000001,1003,4792702,8004,53600
       Short Long Term Debt 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
1,901
366
0
0
0
0
0
0
0000003661,90100000000000000000
       Accounts payable 
0
37
212
173
427
515
673
899
683
213
195
276
329
426
779
653
918
1,517
700
217
715
158
107
721
791
7917211071587152177001,517918653779426329276195213683899673515427173212370
       Other Current Liabilities 
0
24
-4,473
-2,748
433
127
318
205
429
64
108
157
599
81
4
193
289
469
627
586
480
317
994
748
691
69174899431748058662746928919348159915710864429205318127433-2,748-4,473240
   > Long-term Liabilities 
0
0
0
0
0
0
0
0
0
0
2
2
0
560
1,146
0
0
0
0
0
15
42
36
175
152
152175364215000001,1465600220000000000
       Long term Debt Total 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
19
0
0
0
00019000000000000000000000
       Other Liabilities 
0
0
0
0
14
47
23
60
64
23
2
2
0
0
0
0
0
0
0
0
15
23
36
0
2
2036231500000000222364602347140000
> Total Stockholder Equity
0
4,442
7,475
6,323
5,043
4,031
6,940
5,179
1,920
1,087
-185
3,363
1,732
2,050
145
6,787
3,341
4,941
6,575
8,439
7,351
5,644
25,895
23,177
19,617
19,61723,17725,8955,6447,3518,4396,5754,9413,3416,7871452,0501,7323,363-1851,0871,9205,1796,9404,0315,0436,3237,4754,4420
   Common Stock
0
7,458
12,045
12,592
12,592
12,742
16,985
18,730
18,751
20,583
21,459
26,964
27,722
30,025
31,358
40,325
40,335
45,633
53,633
58,372
60,511
62,427
88,361
88,436
88,436
88,43688,43688,36162,42760,51158,37253,63345,63340,33540,32531,35830,02527,72226,96421,45920,58318,75118,73016,98512,74212,59212,59212,0457,4580
   Retained Earnings Total Equity0000000000000000000000000
   Accumulated Other Comprehensive Income 
0
0
-40
-173
0
-479
-645
78
80
273
443
388
595
907
1,208
667
548
2,129
2,470
2,607
3,700
1,133
3,467
3,166
3,236
3,2363,1663,4671,1333,7002,6072,4702,1295486671,2089075953884432738078-645-4790-173-4000
   Capital Surplus 0000000000000000000000000
   Treasury Stock0000000000000000000000000
   Other Stockholders Equity 
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
667
548
2,129
2,470
2,607
4,300
1,133
3,467
3,166
112
1123,1663,4671,1334,3002,6072,4702,129548667000000000000000



Balance Sheet

Currency in AUD. All numbers in thousands.